Cannabis May Help Some People Manage Spinal Cord Injury Pain

For people living with spinal cord injury (SCI), chronic pain can become a lasting complication alongside impaired movement, sensation, and independence. Cannabis is sometimes used to manage that pain, but the available evidence does not show that it repairs spinal cord damage or improves neurological recovery. Its potential role is narrower: symptom relief, with important uncertainties about effectiveness, safety, dosage, and interactions with other treatments.

What the research actually shows

The most directly relevant study is a 2019 qualitative investigation of cannabis use after SCI. In the study by Bourke and colleagues, researchers interviewed eight adults in New Zealand who used cannabis for SCI-related pain. Participants said cannabis reduced pain quickly and, in their view, caused less drowsiness than some prescription medications. Several also felt better able to participate in everyday activities and social roles.

Those reports are useful for understanding patients’ experiences, but they do not establish that cannabis is effective for SCI pain in a clinical trial. The study was small, relied on participants’ self-reports, and did not compare cannabis with a placebo or another treatment. Participants also described inconsistent product strength, uncertain dosing, and difficulties obtaining a reliable supply.

How common is therapeutic cannabis use after SCI?

A 2016 cross-sectional study examined cannabis use among 244 people with chronic SCI. In the published analysis by Drossel, Forchheimer, and Meade, 22.5% of participants reported using cannabis for therapeutic purposes at least monthly. Among those users, 70.4% cited pain relief and 46.3% cited relief of spasticity as reasons for use.

The findings describe who was using cannabis; they do not show that cannabis caused better health outcomes. In fact, cannabis users in the study were more likely to report opioid prescriptions, rather than being less likely to use them. They were also more likely to be single, live alone, report bladder complications, and perceive greater psychosocial difficulties. These associations may reflect underlying differences between users and nonusers, not effects caused by cannabis itself.

The opioid question remains unsettled

Consider a four-year Australian cohort study involving people with chronic non-cancer pain who had been prescribed opioids. However, the study did not demonstrate that cannabis reduced opioid use or improved pain control over time. The Campbell et al. Study was observational, and its results do not support treating cannabis as a proven opioid-sparing therapy.

That distinction matters. People who use cannabis may differ from those who do not in pain severity, health conditions, medication use, access to care, or personal preferences. Such studies can identify patterns and associations, but they cannot reliably determine whether cannabis itself produced a reduction in pain or medication use.

Broader evidence on chronic pain

Evidence from chronic-pain research outside SCI suggests that some cannabis-based medicines may provide modest short-term pain relief for some adults, particularly in neuropathic pain. However, results vary by product, dose, route of administration, and condition. Much of the evidence comes from studies of standardized cannabinoid medicines rather than the commercially available cannabis products used by many patients.

The Agency for Healthcare Research and Quality’s living systematic review emphasizes that both benefits and harms must be considered and that the evidence continues to evolve. The Centers for Disease Control and Prevention’s overview of cannabis and chronic pain likewise notes that evidence is limited for many types of pain and that cannabis can cause unwanted effects.

Why cannabis might affect pain

Cannabis contains cannabinoids, including tetrahydrocannabinol (THC) and cannabidiol (CBD), that interact with the body’s endocannabinoid system. This system is involved in pain processing, inflammation, mood, sleep, and other functions. These biological effects provide a plausible explanation for why some people report symptom relief, but a plausible mechanism is not proof that a treatment improves function or recovery after SCI.

Potential risks and practical limitations

Reported adverse effects of cannabis include dizziness, sedation, impaired attention and memory, and changes in mood or perception. These effects may be particularly important for people with SCI who already face fall risks, mobility limitations, medication-related drowsiness, or complex medical conditions. Cannabis may also affect judgment and can interact with other drugs.

Product quality and dosing are additional concerns. Cannabis products can differ substantially in their THC and CBD concentrations, and labels may not always predict the amount absorbed by the body. Smoking or vaping introduces separate respiratory considerations, while edible products can take longer to act and may increase the risk of taking too much before effects are felt.

What patients and clinicians can conclude

Cannabis may help some individuals feel less pain or function more comfortably, but the SCI-specific evidence is still limited. The strongest directly relevant study documents patients’ experiences rather than proving treatment efficacy, and observational research does not establish that cannabis reduces opioid use or improves long-term outcomes.

There is currently no good evidence that cannabis restores damaged spinal cord tissue, reverses paralysis, or accelerates neurological recovery. Its possible role is as one component of an individualized pain-management plan, not as a substitute for rehabilitation or a proven treatment for the injury itself.

People with SCI who are considering cannabis should discuss the decision with a clinician familiar with their medications, pain type, mental-health history, fall risk, and local laws. Future studies should use standardized products, clinically meaningful measures of function and participation, longer follow-up, and well-designed comparisons with placebo and established treatments.